Craig Devoe
About
Craig Devoe is a scholar working on Oncology, Molecular Biology and Hematology.
According to data from OpenAlex, Craig Devoe has authored 47 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 10 papers in Molecular Biology and 7 papers in Hematology. Recurrent topics in Craig Devoe's work include Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Immunotherapy and Immune Responses (6 papers). Craig Devoe is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Pancreatic and Hepatic Oncology Research (8 papers) and Immunotherapy and Immune Responses (6 papers). Craig Devoe collaborates with scholars based in United States, Russia and France. Craig Devoe's co-authors include Kenar D. Jhaveri, Rimda Wanchoo, Nupur N. Uppal, Gilbert Deray, Valerie S. Barta, Vincent Launay‐Vacher, Sunil R. Hingorani, William Proctor Harris, Sergei Tjulandin and Randall F. Holcombe and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Craig Devoe
45 papers receiving 12.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Craig Devoe United States | 17 | 10.3k | 4.5k | 3.9k | 2.3k | 1.3k | 47 | 12.7k | ||
| Rimda Wanchoo United States | 20 | 9.9k 1.0× | 4.3k 1.0× | 4.0k 1.0× | 2.1k 0.9× | 1.1k 0.9× | 51 | 12.7k | ||
| Nupur N. Uppal United States | 8 | 9.7k 0.9× | 4.3k 1.0× | 3.8k 1.0× | 2.0k 0.9× | 1.1k 0.8× | 25 | 12.1k | ||
| Valerie S. Barta United States | 5 | 9.6k 0.9× | 4.2k 0.9× | 3.7k 1.0× | 2.0k 0.9× | 1.1k 0.8× | 6 | 11.7k | ||
| Laura Q.M. Chow United States | 44 | 9.1k 0.9× | 3.0k 0.7× | 4.6k 1.2× | 2.9k 1.3× | 1.6k 1.3× | 159 | 12.4k | ||
| Scott Gettinger United States | 58 | 10.3k 1.0× | 2.8k 0.6× | 6.8k 1.7× | 2.8k 1.3× | 1.7k 1.4× | 258 | 13.2k | ||
| Michael A. Postow United States | 57 | 12.2k 1.2× | 5.2k 1.2× | 3.1k 0.8× | 2.9k 1.3× | 703 0.6× | 231 | 15.4k | ||
| Axel Hoos United States | 55 | 9.2k 0.9× | 4.7k 1.0× | 2.8k 0.7× | 3.4k 1.5× | 1.1k 0.9× | 142 | 13.4k | ||
| Matteo S. Carlino Australia | 51 | 9.6k 0.9× | 3.7k 0.8× | 2.0k 0.5× | 4.7k 2.1× | 1.5k 1.2× | 303 | 12.5k | ||
| Joseph P. Eder United States | 47 | 8.2k 0.8× | 2.9k 0.6× | 3.2k 0.8× | 3.4k 1.5× | 1.6k 1.3× | 178 | 12.2k | ||
| Steven O’Day United States | 52 | 9.5k 0.9× | 4.6k 1.0× | 2.4k 0.6× | 4.7k 2.1× | 1.4k 1.1× | 198 | 12.9k |
Countries citing papers authored by Craig Devoe
Since
Specialization
Citations
This map shows the geographic impact of Craig Devoe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig Devoe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig Devoe more than expected).
Fields of papers citing papers by Craig Devoe
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Craig Devoe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig Devoe. The network helps show where Craig Devoe may publish in the future.
Co-authorship network of co-authors of Craig Devoe
This figure shows the co-authorship network connecting the top 25 collaborators of Craig Devoe. A scholar is included among the top collaborators of Craig Devoe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig Devoe. Craig Devoe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Wainberg, Zev A., Colin D. Weekes, Muhammad Furqan, et al.. (2025). Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results. Nature Medicine. 31(11). 3648–3653.
2.
Wu, Grace, Daniel A. King, Sepideh Gholami, et al.. (2025). Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. Current Oncology. 32(2). 103–103.
3.
Patel, Sapna P., Víctor M. Prieto, M. J. S. Lowe, et al.. (2025). 1601O 3-year survival with neoadjuvant-adjuvant pembrolizumab from SWOG S1801. Annals of Oncology. 36. S882–S883.
4.
Knox, Jennifer J., Elizabeth M. Jaffee, Grainne M. O’Kane, et al.. (2024). Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.. Journal of Clinical Oncology. 42(17_suppl). LBA4004–LBA4004.
5.
Devoe, Craig, Shubham Pant, Zev A. Wainberg, et al.. (2024). AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 2636–2636.
6.
Pant, Shubham, Zev A. Wainberg, Colin D. Weekes, et al.. (2024). Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nature Medicine. 30(2). 531–542.
7.
Wainberg, Zev A., Vincent Chung, Craig Devoe, et al.. (2024). AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 42(3_suppl). TPS720–TPS720.
8.
Patel, Sapna P., Megan Othus, Paul Wright, et al.. (2023). LBA48 Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Annals of Oncology. 34. S1288–S1288.
9.
Othus, Megan, Víctor M. Prieto, Elizabeth I. Buchbinder, et al.. (2022). LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801). Annals of Oncology. 33. S1408–S1408.
10.
Pant, Shubham, Muhammad Furqan, Vincent Chung, et al.. (2022). First-in-human phase 1 trial of ELI-002 immunotherapy as treatment for subjects with Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma and other solid tumors.. Journal of Clinical Oncology. 40(16_suppl). TPS2701–TPS2701.
11.
Shapiro, Geoffrey I., Robert Wesolowski, Craig Devoe, et al.. (2021). Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer. 125(4). 520–527.
12.
Devoe, Craig, et al.. (2019). Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma. SHILAP Revista de lepidopterología. 2019. 1–3.
13.
Devoe, Craig, et al.. (2019). Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. PubMed. 3(1). e1–e4.
14.
Schrock, Alexa B., Dean C. Pavlick, Samuel J. Klempner, et al.. (2018). Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus. Clinical Cancer Research. 24(8). 1881–1890.
15.
Wanchoo, Rimda, Nupur N. Uppal, Valerie S. Barta, et al.. (2017). Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review. American Journal of Nephrology. 45(2). 160–169.
16.
Hingorani, Sunil R., William Proctor Harris, J. Thaddeus Beck, et al.. (2016). Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clinical Cancer Research. 22(12). 2848–2854.
17.
Shapiro, Geoffrey I., Robert Wesolowski, Mark R. Middleton, et al.. (2016). Abstract CT012: Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). Cancer Research. 76(14_Supplement). CT012–CT012.
18.
Leung, Sam H., et al.. (2015). A case of acute kidney injury from crystal nephropathy secondary to pomalidomide and levofloxacin use. Journal of Oncology Pharmacy Practice. 22(2). 357–360.
19.
Zhang, Xinmin, Peter Farmer, Mansoor Nasim, et al.. (2012). Central nervous system lymphoma in immunocompetent patients: The North Shore-Long Island Jewish Health System experience. Journal of Clinical Neuroscience. 20(1). 75–79.
20.
Cannon, Mark, et al.. (2006). Prevention of mucositis in AutoBMT/stem cell transplant patients. Biology of Blood and Marrow Transplantation. 12(2). 100–101.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Rimda Wanchoo Breakdown of academic impact, for papers by Nupur N. Uppal Breakdown of academic impact, for papers by Valerie S. Barta Breakdown of academic impact, for papers by Laura Q.M. Chow Breakdown of academic impact, for papers by Scott Gettinger Breakdown of academic impact, for papers by Michael A. Postow Breakdown of academic impact, for papers by Axel Hoos Breakdown of academic impact, for papers by Matteo S. Carlino Breakdown of academic impact, for papers by Joseph P. Eder Breakdown of academic impact, for papers by Steven O’Day